KALV at a glance
KalVista Pharmaceuticals, Inc. (KALV, SEC CIK 1348911) filed its latest 10-K annual report on July 10, 2025, a 10-Q quarterly report on May 14, 2026, an 8-K current report on June 11, 2026 and Form 4 insider filings as recently as June 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended April 30, 2024 (FY2024), KalVista Pharmaceuticals, Inc. (KALV) reported revenue of $50.0 million and a net loss of $126.6 million. Diluted EPS was -$3.44.
- As of March 31, 2026, 25 institutional investment managers tracked by SignalX reported holding KalVista Pharmaceuticals, Inc. (KALV) shares worth $279.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2024
- $50.0M
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 25 funds
- $279.5M · +3 vs prior quarter
- Latest 8-K
- Jun 11, 2026
- Item 1.02 · Item 1.01 · Item 2.01 · Item 3.01 · Item 7.01 · Item 5.02 · Item 5.03
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Mar 31, 2026
Risk Factors
- New transaction risk: Chiesi merger may fail or be delayed, requiring 50%+1 tendered shares and antitrust approvals
- Regulatory risk: HSR Act and foreign investment approvals could delay or prevent closing
- Operational risk: Interim covenants restrict acquisitions, investments, indebtedness, and capital expenditures during the pending merger
- Financial risk: Termination under specified circumstances could require KalVista to pay Chiesi $66.4 million
- Market risk: Prolonged offer period could impair employee retention and relationships with customers, vendors, and collaborators
AI summary of the KALV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.02: Termination of a Material Definitive Agreement
- Termination of KalVista’s 2015, 2017, and 2021 equity incentive plans upon Offer and Merger closing
- Employee stock purchase plan terminated immediately before the Merger’s Effective Time
Item 1.01: Entry into a Material Definitive Agreement
- Supplemental indenture triggered by merger, modifying conversion mechanics for 3.250% Convertible Senior Notes due 2031
- Each $1,000 note converts into $1,606.28 cash at and after merger closing
Item 2.01: Completion of Acquisition or Disposition of Assets
- KalVista shares ceased Nasdaq Global Market trading before the June 11, 2026 market open
- Merger consummation triggered delisting and Nasdaq Form 25 filing
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule
- Offer and merger closed, transferring KalVista control to Parent through Purchaser
- Parent funded merger consideration with cash on hand and financing
Item 7.01: Regulation FD Disclosure
- Standard Regulation FD disclaimer language, not substantive company disclosure
- No investor-actionable operating, financial, or strategic information in the provided excerpt
Item EX-99.1: Item EX-99.1
- Chiesi completed KalVista acquisition on June 11, 2026, making KalVista a wholly owned subsidiary
- Cash consideration fixed at $27.00 per share, with 77.8% of outstanding shares tendered
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Merger-installed governance: eight directors resigned, with John Hess becoming sole director and a Company officer
- Departures unrelated to operational disagreements, indicating transaction-driven leadership transition
Item 5.03: Amendments to Articles of Incorporation or Bylaws
- Certificate of incorporation and bylaws amended and restated in full as of the Effective Time
- Revised governing documents filed as Exhibits 3.1 and 3.2
Item 1.01: Entry into a Material Definitive Agreement
- Chiesi agreed to acquire KalVista for $27.00 cash per share, making the transaction price the primary near-term valuation reference
- Tender offer launch due within 10 business days, expiring after 20 business days unless extended
Item EX-99.1: Item EX-99.1
- Chiesi agreed to acquire KalVista for $27.00 per share in cash, valuing equity at approximately $1.9bn
- Offer represents a 36% premium to KalVista’s 30-day volume-weighted average price as of April 28, 2026
Item 7.01: Regulation FD Disclosure
- Boilerplate Reg FD disclaimer, not substantive business disclosure
- Exhibit information excluded from Exchange Act Section 18 liability
AI summaries of KALV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KALV
Don't miss the next KALV filing
- Alerts as it files. A push when KALV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KALV, by share count.
- Ask anything. An AI agent that reads every KALV filing and answers with sources.
KALV alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Stuart Nancy | D | Jun 11, 2026 | 30,000 | - |
| Unkart Edward W | D | Jun 11, 2026 | 10,000 | - |
| Treanor Patrick | D | Jun 11, 2026 | 17,000 | - |
| Sensenig Bethany | D | Jun 11, 2026 | 45,000 | - |
| Reid Laurence | D | Jun 11, 2026 | 17,000 | - |
| Fairey William | D | Jun 11, 2026 | 17,000 | - |
| Stuart Nancy | D | Jun 11, 2026 | 14,000 | - |
| Stuart Nancy | D | Jun 11, 2026 | 10,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $50.0M | - |
| Operating Income | -$110.9M | -$140.4M | -$188.0M |
| Net Income | -$92.9M | -$126.6M | -$183.4M |
| Op. Margin | - | -280.9% | - |
| Net Margin | - | -253.3% | - |
| Balance Sheet | |||
| Total Assets | - | $235.4M | $250.8M |
| Equity | $161.0M | $206.6M | $95.4M |
| ROE | -57.7% | -61.3% | -192.3% |
| Per Share | |||
| EPS | - | $-3.44 | $-3.69 |
| Cash Flow | |||
| Operating CF | -$75.3M | -$89.2M | -$152.9M |
| CapEx | $1.2M | $42K | $434K |
Source: XBRL data in KalVista Pharmaceuticals, Inc. (KALV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate KALV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q1 2026 | 25 | $279.5M |
| Q4 2025 | 22 | $238.8M |
| Q3 2025 | 22 | $168.4M |
| Q2 2025 | 23 | $117.4M |
| Q1 2025 | 19 | $72.9M |
| Q4 2024 | 13 | $44.5M |
| Q3 2024 | 11 | $31.8M |
- Citigroup+233.5K (+2168%)
- Ameriprise Financial+195.1K (+558%)
- Bank of America Corp+165.8K (+43%)
- FMR LLC (Fidelity)+76.0K (+68%)
- State Street Corp+44.2K (+2%)
- Millennium Management−1.01M (-35%)
- Morgan Stanley−261.1K (-37%)
- BNY Mellon−110.8K (-16%)
- Wells Fargo & Co−32.1K (-57%)
- Goldman Sachs Group−11.0K (-1%)
- Vanguard Capital Management LLC+1.83M
- Vanguard Portfolio Management LLC+362.9K
- Two Sigma Investments+153.5K
- Marex Group plc+20.0K
- Fifth Third Bancorp+519
- Vanguard Group Inc−2.51M
- Renaissance Technologies LLC−165.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 135 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KALV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Aug 11, 2026 | - | - | |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| SC 13G | Jun 10, 2026 | - | - | |
| 4 | May 29, 2026 | - | - | |
| 4 | May 27, 2026 | - | - | |
| 4 | May 27, 2026 | - | - | |
| 4 | May 27, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - | |
| 4 | May 26, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
KALV SEC filings: frequently asked questions
Which institutions hold KALV stock?
As of March 31, 2026, the largest KalVista Pharmaceuticals, Inc. (KALV) holders among the 13F filers tracked by SignalX were BlackRock ($76.4 million), State Street Corp ($39.4 million), Millennium Management ($38.5 million), Vanguard Capital Management LLC ($36.8 million), Goldman Sachs Group ($16.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was KALV's revenue in fiscal year 2024?
For the fiscal year ended April 30, 2024 (FY2024), KalVista Pharmaceuticals, Inc. (KALV) reported revenue of $50.0 million and a net loss of $126.6 million. Diluted EPS was -$3.44. The figures come from the XBRL data in the 10-K.
What did KALV report in its latest 8-K?
KalVista Pharmaceuticals, Inc. (KALV) filed an 8-K on June 11, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule), Item 7.01 (Regulation FD Disclosure), Item 5.02 (Departure/Appointment of Directors or Principal Officers) and Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Termination of KalVista’s 2015, 2017, and 2021 equity incentive plans upon Offer and Merger closing.
What are the latest KALV SEC filings?
KalVista Pharmaceuticals, Inc. (KALV) filed its latest 10-K annual report on July 10, 2025, a 10-Q quarterly report on May 14, 2026, an 8-K current report on June 11, 2026 and a Form 4 insider filing on June 11, 2026.
What is KALV's SEC CIK number?
KalVista Pharmaceuticals, Inc. (KALV)'s SEC Central Index Key (CIK) is 1348911. EDGAR lists every KALV filing under that number.
Ask anything about KALV
The research agent reads KALV's filings, financials, insider trades and 13F holders, then answers with sources.